SCHEDULE: Janus Henderson Boosts Stake in LEXEO THERAPEUTICS to 11.3%

Janus Henderson Group plc, through its subsidiaries, reported an 11.3% beneficial ownership stake in LEXEO THERAPEUTICS, INC. as of September 30, 2025.

Summary

• Janus Henderson Group plc and its affiliates beneficially own 6,100,406 shares of LEXEO THERAPEUTICS, INC. common stock.
• This represents 11.3% of the issuer's class of securities.
• The ownership is held in the ordinary course of business and not for the purpose of changing or influencing control of LEXEO THERAPEUTICS.
• Janus Henderson Biotech Innovation Master Fund Ltd, an investment vehicle under Janus Henderson, holds 4,076,465 shares, representing 7.6% of the class.
• The filing is an Amendment No. 6 to a Schedule 13G, indicating an update to a previously reported beneficial ownership position.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by a reputable institutional investor like Janus Henderson Group plc generally indicates a vote of confidence in the issuer's prospects, suggesting a positive sentiment.

Positives

• Janus Henderson Group plc, a significant institutional investor, reported an 11.3% beneficial ownership stake in LEXEO THERAPEUTICS, indicating a vote of confidence in the company's prospects.

Negatives

• The filing itself, being a beneficial ownership report, does not inherently contain negative information regarding the issuer's operations or financial performance.

Risks

• The Schedule 13G filing does not disclose specific risks related to LEXEO THERAPEUTICS, INC.'s operations or financial condition.

Future Outlook

The Schedule 13G filing does not contain any forward-looking statements or guidance from the issuer.

Industry Context

A significant stake by a major investment firm like Janus Henderson in a biotech company like LEXEO THERAPEUTICS suggests institutional interest in the company's potential, which is common in the biotech sector where long-term growth and innovation drive investment.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Increased institutional ownership can provide stability and potentially attract further institutional interest, signaling confidence in the company.
• Company Management: A large institutional holder may exert influence through voting power, though the filing states the shares are not held for control purposes.

Key Dates

Recommendation

The filing indicates a significant institutional stake, which is generally a positive signal of confidence. However, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It suggests the stock is worth holding for investors who already own it, given the institutional backing, but doesn't offer new fundamental reasons for immediate action.

Keywords

LEXEO THERAPEUTICS, Janus Henderson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotech, Investment Adviser, Holding Company